Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.
Analyst Ratings for MasTec
Analysts have provided the following ratings for MasTec (NYSE:MTZ) within the last quarter:
Oppenheimer Downgrades PLx Pharma to Perform
Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.
Related Posts
5 Analysts Have This to Say About Teradata
Within the last quarter, Teradata (NYSE:TDC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.